HC Wainwright Comments on Evommune’s Q1 Earnings (NYSE:EVMN)

Evommune, Inc. (NYSE:EVMN) – Research analysts at HC Wainwright dropped their Q1 2026 EPS estimates for Evommune in a report issued on Wednesday, March 18th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.83) per share for the quarter, down from their previous estimate of ($0.36). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. HC Wainwright also issued estimates for Evommune’s Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($3.00) EPS.

A number of other research analysts have also recently commented on EVMN. Zacks Research upgraded shares of Evommune to a “hold” rating in a research report on Tuesday, December 2nd. Cantor Fitzgerald began coverage on shares of Evommune in a research note on Monday, December 1st. They issued an “overweight” rating for the company. Leerink Partners began coverage on shares of Evommune in a report on Monday, December 1st. They set an “outperform” rating and a $42.00 target price on the stock. The Goldman Sachs Group upgraded shares of Evommune to a “buy” rating in a research report on Wednesday, January 7th. Finally, William Blair initiated coverage on shares of Evommune in a research report on Monday, December 1st. They set an “outperform” rating for the company. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $47.17.

Evommune Stock Down 3.2%

NYSE:EVMN opened at $23.32 on Friday. The company has a market cap of $839.76 million and a P/E ratio of -2.89. The stock has a 50 day moving average price of $23.26. Evommune has a 1-year low of $13.89 and a 1-year high of $33.20.

Evommune (NYSE:EVMN) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.61).

Institutional Investors Weigh In On Evommune

Institutional investors have recently added to or reduced their stakes in the company. State Street Corp bought a new stake in Evommune in the 4th quarter worth $539,000. Oxford Asset Management LLP bought a new position in shares of Evommune during the fourth quarter valued at about $335,000. XTX Topco Ltd purchased a new stake in shares of Evommune during the fourth quarter worth about $321,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Evommune during the fourth quarter worth about $179,000. Finally, Sofinnova Investments Inc. bought a new stake in shares of Evommune in the fourth quarter worth about $2,625,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.